Key Highlights
● Leerink Partners downgraded Bristol-Myers to Market Perform and cut its price target to $59 from $73.
● The downgrade centered on three pipeline drugs: admilparant, milvexian and Cobenfy.
● Health care broadly lagged, with Merck the Dow's worst performer and Pfizer also slipping.
Bristol-Myers Squibb shares fell on Monday after Leerink Partners downgraded the drugmaker and cut its price target, citing risks around several key pipeline drugs.
Downgrade hits the drugmaker
Bristol-Myers Squibb (NYSE:BMY) fell on Monday, Oct. 5, landing among the weaker stocks in the S&P 500. Shares were put at about $58.81 after the drop. Reports differed slightly on the exact size of the decline, but all showed a clear fall.
The catalyst was an analyst call. Leerink Partners analyst David Risinger downgraded Bristol-Myers to Market Perform from Outperform and cut his price target to $59 from $73.
Risinger explained the shift in plain terms: "We changed our Investment thesis after conducting more detailed assessments of key pipeline candidates reading out over the next several months."
Three pipeline drugs under the microscope
Leerink's concerns centered on three products. The first is admilparant, an experimental treatment for fibrotic disease. The second is milvexian, an anticoagulant that would compete with Eliquis, the blood thinner that has long been one of Bristol-Myers' biggest sellers. The third is Cobenfy, the company's antipsychotic, where the question is how quickly doctors and patients adopt it.
Big drugmakers rely on new medicines to replace Revenue from older drugs as they age. That makes upcoming trial readouts a major driver of how investors value companies like Bristol-Myers. When an analyst becomes less confident about those readouts, the stock can reprice quickly.
The new $59 target sits close to where the shares ended Monday.
Health care lags a record-setting market
Bristol-Myers had company in the red. Health care was the weakest sector at midday, and big pharmaceutical names struggled. Merck (NYSE:MRK) was the worst performer on the Dow Jones Industrial Average, Johnson & Johnson (NYSE:JNJ) fell, and Pfizer (NYSE:PFE) slipped. Vaccines were in focus after Vaxcyte (NASDAQ:PCVX) reported strong late-stage data for its pneumococcal shot.
Not every health care stock struggled. Life-science tools makers bucked the trend, led by Charles River Laboratories (NYSE:CRL), which rallied to a 52-week high.
The broader market was firmer. The S&P 500 rose 51.23 points to 7,773.95, just shy of its summer record. The Nasdaq Composite climbed 286.45 points to a record close of 27,477.31, while the Dow added 90.94 points to 51,267.90. Big technology and artificial-intelligence stocks led the way.
Rates and data in the background
The macro picture was mixed. Friday's jobs report showed employers added only 29,000 jobs in September, which cut bets on a Federal Reserve rate hike in October. Traders now see roughly a one-in-four or smaller chance of such a move, down from better than even a week ago.
Yet long-term borrowing costs kept rising. The 10-year Treasury Yield climbed to its highest close since 2002, as Inflation worries lingered. The ISM services prices-paid index rose to its highest level since July 2022.
Oil eased, with Brent settling at $100.32 a barrel after G7 nations agreed to release emergency reserves, even as the Strait of Hormuz remains effectively closed.
What to watch
For Bristol-Myers, the key test is the run of pipeline readouts that Leerink says are due over the next several months. Results for admilparant, milvexian and Cobenfy will shape whether analysts grow more or less cautious. The company's next Quarterly Report will also be closely watched. On the macro front, the Federal Reserve releases minutes from its September meeting on Wednesday, Oct. 7, at 2pm ET, and the Fed meets again on Oct. 27-28.






Please wait processing your request...